Next Article in Journal
Increased ACh-Associated Immunoreactivity in Autonomic Centers in PTZ Kindling Model of Epilepsy
Previous Article in Journal
Aristolochia trilobata: Identification of the Anti-Inflammatory and Antinociceptive Effects
Open AccessReview

Mesenchymal Stem Cells: A Trump Card for the Treatment of Diabetes?

Experimental Neurology Unit and Milan Center for Neuroscience, School of Medicine and Surgery, University of Milano-Bicocca, Via Cadore 48, 20900 Monza, Italy
*
Author to whom correspondence should be addressed.
Biomedicines 2020, 8(5), 112; https://doi.org/10.3390/biomedicines8050112
Received: 25 March 2020 / Revised: 30 April 2020 / Accepted: 4 May 2020 / Published: 6 May 2020
(This article belongs to the Section Gene and Cell Therapy)
The advent of the new revolutionary approach based on regenerative medicine is progressively reshaping the therapeutic scenario of many different diseases, such as cardiovascular diseases and immune diseases, with encouraging results. During the last 10 years, many studies have also proposed the use of mesenchymal stem cells (MSCs), adult stem cells with several interesting properties already used in different experimental models, for the treatment of diabetes, however, reporting conflicting outcomes. These reasons have given rise to a question: are these cells a real trump card for the biomedical field? Are they really able to outclass the traditional therapies, or at least able to give an advantage over them? In this review, we will discuss the most promising results obtained with MSCs for the treatment of diabetes and its complications, we will compare the different therapeutic treatments applied as well as the most likely mechanisms of action, and overall we will give an in-depth overview of the pros and the cons of the use of MSCs for the therapy of both type-1 and type-2 diabetes. View Full-Text
Keywords: type-1 diabetes; type-2 diabetes; mesenchymal stem cells; pancreatic islets transplantation; insulin; immune suppression type-1 diabetes; type-2 diabetes; mesenchymal stem cells; pancreatic islets transplantation; insulin; immune suppression
Show Figures

Figure 1

MDPI and ACS Style

Donzelli, E.; Scuteri, A. Mesenchymal Stem Cells: A Trump Card for the Treatment of Diabetes? Biomedicines 2020, 8, 112.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop